|
1
|
Yang J, Liu Y, Wang B, Lan H, Liu Y, Chen
F, Zhang J and Luo J: Sumoylation in p27kip1 via RanBP2 promotes
cancer cell growth in cholangiocarcinoma cell line QBC939. BMC Mol
Biol. 18:232017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sha M, Jeong S and Xia Q: Antiviral
therapy improves survival in patients with HBV infection and
intrahepatic cholangiocarcinoma undergoing liver resection: Novel
concerns. J Hepatol. 68:1315–1316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jin Y, Gao J, Weng Q, Xiong F, Gu S,
Shivaram G, Zhang F and Yang X: Cholangiocarcinoma: Molecular
imaging-guided radiofrequency hyperthermia-enhanced intratumoral
herpes simplex virus thymidine kinase gene therapy. Am J Cancer
Res. 8:502–513. 2018.PubMed/NCBI
|
|
4
|
Suksawat M, Techasen A, Namwat N, Boonsong
T, Titapun A, Ungarreevittaya P, Yongvanit P and Loilome W:
Inhibition of endothelial nitric oxide synthase in
cholangiocarcinoma cell lines-a new strategy for therapy. FEBS Open
Bio. 8:513–522. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshikawa D, Ojima H, Kokubu A, Ochiya T,
Kasai S, Hirohashi S and Shibata T: Vandetanib (ZD6474), an
inhibitor of VEGFR and EGFR signalling, as a novel
molecular-targeted therapy against cholangiocarcinoma. Br J Cancer.
100:1257–1266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chiu HS, Somvanshi S, Patel E, Chen TW,
Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome
Atlas Research Network, ; et al: Pan-cancer analysis of lncRNA
regulation supports their targeting of cancer genes in each tumor
context. Cell Rep. 23:297–312.e12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vrba L and Futscher BW: Epigenetic
silencing of lncRNA MORT in 16 TCGA cancer types. F1000Res.
7:2112018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang G, Pian C, Chen Z, Zhang J, Xu M,
Zhang L and Chen Y: Identification of cancer-related miRNA-lncRNA
biomarkers using a basic miRNA-lncRNA network. PLoS One.
13:e1966812018.
|
|
9
|
Lou Y, Jiang H, Cui Z, Wang X, Wang L and
Han Y: Gene microarray analysis of lncRNA and mRNA expression
profiles in patients with high-grade ovarian serous cancer. Int J
Mol Med. 42:91–104. 2018.PubMed/NCBI
|
|
10
|
Sun T, Du SY, Armenia J, Qu F, Fan J, Wang
X, Fei T, Komura K, Liu SX, Lee GM and Kantoff PW: Expression of
lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter
facilitates the development of castration-resistant prostate
cancer. Oncogenesis. 7:302018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang H, Huo X, Yang XR, He J, Cheng L,
Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated
upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer
metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv L, Wei M, Lin P, Chen Z, Gong P, Quan Z
and Tang Z: Integrated mRNA and lncRNA expression profiling for
exploring metastatic biomarkers of human intrahepatic
cholangiocarcinoma. Am J Cancer Res. 7:688–699. 2017.PubMed/NCBI
|
|
13
|
Guo L, Zhou Y, Chen Y, Sun H, Wang Y and
Qu Y: LncRNA ASAP1-IT1 positively modulates the development of
cholangiocarcinoma via hedgehog signaling pathway. Biomed
Pharmacother. 103:167–173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li
C, Kang P, Leng K, Ji D, Li Z, et al: SP1-induced upregulation of
lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding
EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J
Exp Clin Cancer Res. 37:812018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi X, Zhang H, Wang M, Xu X, Zhao Y, He
R, Zhang M, Zhou M, Li X, Peng F, et al: LncRNA AFAP1-AS1 promotes
growth and metastasis of cholangiocarcinoma cells. Oncotarget.
8:58394–58404. 2017.PubMed/NCBI
|
|
16
|
Zhang S, Xiao J, Chai Y, Du YY, Liu Z,
Huang K, Zhou X and Zhou W: LncRNA-CCAT1 promotes migration,
invasion, and EMT in intrahepatic cholangiocarcinoma through
suppressing miR-152. Dig Dis Sci. 62:3050–3058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang C, Li JY, Tian FZ, Zhao G, Hu H, Ma
YF and Yang YL: LncRNA NEAT1 promotes growth and metastasis of
cholangiocarcinoma cells. Oncol Res. 26:879–888. 2018. View Article : Google Scholar
|
|
18
|
Jiang XM, Li ZL, Li JL, Zheng WY, Li XH,
Cui YF and Sun DJ: LncRNA CCAT1 as the unfavorable prognostic
biomarker for cholangiocarcinoma. Eur Rev Med Pharmacol Sci.
21:1242–1247. 2017.PubMed/NCBI
|
|
19
|
Igami T, Ebata T, Yokoyama Y, Sugawara G,
Takahashi Y and Nagino M: Staging of peripheral-type intrahepatic
cholangiocarcinoma: Appraisal of the new TNM classification and its
modifications. World J Surg. 35:2501–2509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y
and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell
metastasis by inhibiting PGC-1α expression. Cell Death Dis.
7:e21592016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jing LL and Mo XM: Reduced miR-485-5p
expression predicts poor prognosis in patients with gastric cancer.
Eur Rev Med Pharmacol Sci. 20:1516–1520. 2016.PubMed/NCBI
|
|
23
|
Zheng B, Jeong S, Zhu Y, Chen L and Xia Q:
miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA).
Oncotarget. 8:100819–100830. 2017.PubMed/NCBI
|
|
24
|
Zhang K, Zhao Z, Yu J, Chen W, Xu Q and
Chen L: LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate
cancer cell proliferation, migration, and invasion in
hepatocellular carcinoma. J Cell Biochem. 119:6045–6056. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu B, Yan S, Jia Y, Ma J, Wu S, Xu Y,
Shang M and Mao A: TLR2 promotes human intrahepatic
cholangiocarcinoma cell migration and invasion by modulating NF-κB
pathway-mediated inflammatory responses. FEBS J. 283:3839–3850.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ince AT, Yildiz K, Gangarapu V, Kayar Y,
Baysal B, Karatepe O, Kemik AS and Şentürk H: Serum and biliary
MMP-9 and TIMP-1 concentrations in the diagnosis of
cholangiocarcinoma. Int J Clin Exp Med. 8:2734–2740.
2015.PubMed/NCBI
|
|
27
|
Wang Q, Tang H, Yin S and Dong C:
Downregulation of microRNA-138 enhances the proliferation,
migration and invasion of cholangiocarcinoma cells through the
upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep. 29:2046–2052.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M, Cai WR, Meng R, Chi JR, Li YR,
Chen AX, Yu Y and Cao XC: miR-485-5p suppresses breast cancer
progression and chemosensitivity by targeting survivin. Biochem
Biophys Res Commun. 501:48–54. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duan J, Zhang H, Li S, Wang X, Yang H,
Jiao S and Ba Y: The role of miR-485-5p/NUDT1 axis in gastric
cancer. Cancer Cell Int. 17:922017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kang M, Ren MP, Zhao L, Li CP and Deng MM:
miR-485-5p acts as a negative regulator in gastric cancer
progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222.
2015.PubMed/NCBI
|
